Biological response modifiers: their potential and limitations in cancer therapeutics.
Mihich
E
E
D000276:Adjuvants, Immunologic / Q000627:therapeutic use / Q000633:toxicity; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D001500:BCG Vaccine / Q000627:therapeutic use; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D008222:Lymphokines / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D013947:Thymosin / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D008222:Lymphokines; D013947:Thymosin; D007372:Interferons